The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis

Gynecologic Oncology

Volumn 117, Issue 3, 2010, Pages 417-422

  En lin, Song ^a   Sheng guo, Chen ^a   Hua qiao, Wang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Epidermal growth factor containing fibulin like extracellular matrix protein 1; Hybridization in situ; Immunohistochemistry; Microvascular density; Prognosis

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR CONTAINING FIBULIN LIKE EXTRACELLULAR MATRIX PROTEIN 1; FIBULIN; MESSENGER RNA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROVASCULAR DENSITY; MICROVASCULARIZATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; STAINING; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIGENS, CD34; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RNA, MESSENGER; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 77951938614     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.12.016     Document Type: Article

References (30)

1. Folkman J. The role of angiogenesis in tumor growth. Semin. Cancer Biol. 3 2 (1992) 65-71
2. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 6801 (2000) 249-257
3. Tjalma W., et al. Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer. Br. J. Cancer 78 2 (1998) 170-174
4. Cooper R.A., et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin. Cancer Res. 4 11 (1998) 2795-2800
5. West C.M., et al. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 61 7 (2001) 2907-2910
6. Phoophitphong T., et al. Correlation of angiogenesis and recurrence-free survival of early stage cervical cancer patients undergoing radical hysterectomy with pelvic lymph node dissection. J. Obstet. Gynaecol. Res. 33 6 (2007) 840-848
7. Timpl R., et al. Fibulins: a versatile family of extracellular matrix proteins. Nat. Rev. Mol. Cell. Biol. 4 6 (2003) 479-489
8. Argraves W.S., et al. Fibulins: physiological and disease perspectives. EMBO Rep. 4 12 (2003) 1127-1131
9. Kobayashi N., et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization. J. Biol. Chem. 282 16 (2007) 11805-11816
10. Pupa S.M., et al. Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene 23 12 (2004) 2153-2160
11. Pupa S.M., et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67 9 (2007) 4271-4277
12. Yi C.H., et al. Loss of fibulin-2 expression is associated with breast cancer progression. Am. J. Pathol. 170 5 (2007) 1535-1545
13. Gallagher W.M., et al. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. FEBS Lett. 489 1 (2001) 59-66
14. Schiemann W.P., et al. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J. Biol. Chem. 277 30 (2002) 27367-27377
15. Lecka-Czernik B., Lumpkin C., and Goldstein S. An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol. Cell. Biol. 15 1 (1995) 120-128
16. Stone E.M., et al. A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat. Genet. 22 2 (1999) 199-202
17. Roybal C.N., et al. Aberrant accumulation of fibulin-3 in the endoplasmic reticulum leads to activation of the unfolded protein response and VEGF expression. Invest. Ophthalmol. Vis. Sci. 46 11 (2005) 3973-3979
18. Marmorstein L.Y., et al. Aberrant accumulation of EFEMP1 underlies drusen formation in Malattia Leventinese and age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 99 20 (2002) 13067-13072
19. Albig A.R., Neil J.R., and Schiemann W.P. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66 5 (2006) 2621-2629
20. Sadr-Nabavi A., et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int. J. Cancer 124 7 (2009) 1727-1735
21. Seeliger H., et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol. Cancer Res. 7 2 (2009) 189-198
22. Weidner N., et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84 24 (1992) 1875-1887
23. Albig A.R., and Schiemann W.P. Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell. Biol. 23 6 (2004) 367-379
24. Shibata M.A., et al. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther. 15 12 (2008) 776-786
25. Chen L., et al. Influence of microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol. Rep. 21 4 (2009) 917-923
26. Lorger M., et al. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. U. S. A. 106 26 (2009) 10666-10671
27. duPre' S.A., Redelman D., and Hunter K. Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp. Mol. Pathol. 85 3 (2008) 174-188
28. Giehl K., and Menke A. Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front. Biosci. 13 (2008) 3975-3985
29. Klenotic P.A., et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) Implications for macular degenerations. J. Biol. Chem. 279 29 (2004) 30469-30473
30. Qi J.H., et al. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat. Med. 9 4 (2003) 407-415